TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15843668

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 94

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 94
Study: 12027844

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg
Number of subjects: 20
Study: 10340912

Group type: EXPERIMENTAL
Intervention: SB 209670 infusion at doses ranging from 0.2 to 1.5 microg kg(‐1) min(‐1) for approximately 8 hours
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 27
Study: 7582196

Group type: EXPERIMENTAL
Intervention: Cilazapril 2 mg daily, starting 7 days before PTCA and continuing for 6 months
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (no cilazapril)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Cilazapril group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study: 1819425

Group type: EXPERIMENTAL
Intervention: Silicone and sodium iodide diffusers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7020181

Group type: EXPERIMENTAL
Intervention: Angiography on days 5 to 11 after transplantation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no angiography)
Number of subjects: 25
Study: 31054032

Group type: EXPERIMENTAL
Intervention: Web-based women's health survivorship care plan (SCP)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Attention control (curated resource lists)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Web-based women's health SCP
Number of subjects: 182
Study: 28523795

Group type: EXPERIMENTAL
Intervention: Oral health literacy intervention (5 sessions, 1.5 hours each over 1 year)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Oral health literacy intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 26505179

Group type: EXPERIMENTAL
Intervention: Aftercare over the telephone or face-to-face (up to 4 conversations over 3 months)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Aftercare over the telephone or face-to-face
Number of subjects: 201

Group type: COMPARATOR
Intervention: Aftercare over the telephone
Number of subjects: 201
Study: 23859530

Group type: EXPERIMENTAL
Intervention: Dissection after ligation (group 1)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Dissection before ligation (group 2)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study: 22017192

Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg/day
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 18665392

Group type: EXPERIMENTAL
Intervention: Task with two target-items in a stream of visual objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task with only a single target
Number of subjects: 0
Study: 17335326

Group type: EXPERIMENTAL
Intervention: MLR methylphenidate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15211008

Group type: EXPERIMENTAL
Intervention: Ceramic water filters
Number of subjects: 50

Group type: COMPARATOR
Intervention: Customary water handling practices (Control)
Number of subjects: 50
Study: 12053493

Group type: EXPERIMENTAL
Intervention: NIR stent with on-line visual IVUS criteria for optimization
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wallstent with on-line visual IVUS criteria for optimization
Number of subjects: 70
Study: 9241623

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5‐5 mg daily)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo for Simvastatin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo for Enalapril
Number of subjects: 107
Study: 8517105

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All concentrations of ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AREMG method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sensory blockade
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Partial motor block
Number of subjects: 30
Study: 3430295

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Griseofulvin 1 g daily
Number of subjects: 29
Study: 31665912

Group type: EXPERIMENTAL
Intervention: Combination of intrapancreatic autologous stem cell (ASC) infusion and hyperbaric oxygen treatment (HBOT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 23
Study: 27498549

Group type: EXPERIMENTAL
Intervention: DHEA‐S plasma levels in chronic neck pain group
Number of subjects: 12

Group type: COMPARATOR
Intervention: DHEA‐S plasma levels in control group
Number of subjects: 12

Group type: COMPARATOR
Intervention: DHEA‐S response after physical exercise in control group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DHEA‐S response after physical exercise in chronic neck pain group
Number of subjects: 12
Study: 26067559

Group type: EXPERIMENTAL
Intervention: External splint trimmed above the osteotomy lines (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: External splint extended beyond the osteotomy lines (Group 1)
Number of subjects: 40
Study: 23375693

Group type: EXPERIMENTAL
Intervention: 6-food elimination diet for 6 weeks
Number of subjects: 67
Study: 20717048

Group type: EXPERIMENTAL
Intervention: Anterior lens capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitomycin-C
Number of subjects: 0
Study: 19615288

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg orally daily + vinorelbine 25-30 mg/m² i.v. on D1 and D8 + cisplatin 70-80 mg/m² i.v. on D1
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vinorelbine 25-30 mg/m² i.v. on D1 and D8 + cisplatin 70-80 mg/m² i.v. on D1
Number of subjects: 66
Study: 17414229

Group type: EXPERIMENTAL
Intervention: Prasugrel (LD/MD: 20/5 mg, 30/7.5 mg, 40/10 mg, 60/15 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Prasugrel plus ASA (325 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg LD/75 mg MD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: ASA alone
Number of subjects: 43
Study: 14756599

Group type: EXPERIMENTAL
Intervention: Benefit finding
Number of subjects: 364
Study: 11853116

Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Drug-free and drug-naive patients
Number of subjects: 15
Study: 9855481

Group type: EXPERIMENTAL
Intervention: Good blenders (odorants selected to blend well in mixtures)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Poor blenders (odorants that blended poorly in mixtures)
Number of subjects: 41
Study: 8005776

Group type: EXPERIMENTAL
Intervention: Attitudes towards ex-mental patients' work behaviour
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Government provision for ex-mental patients
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Awareness of welfare policies
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Social welfare policy
Number of subjects: 480
Study: 2804589

Group type: EXPERIMENTAL
Intervention: Adjusted low dose heparin prophylaxis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fixed low dose heparin prophylaxis (calcium heparin 5000 units, 8‐hourly)
Number of subjects: 100
Study: 5328359

Group type: EXPERIMENTAL
Intervention: Protryptiline (10 mg three times daily, max 60 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Imipramine and Amitryptiline (control group)
Number of subjects: 20
Study: 29704016

Group type: EXPERIMENTAL
Intervention: Exercise to strengthen the back muscles after surgery
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 152
Study: 29354915

Group type: EXPERIMENTAL
Intervention: Combination of acupoint catgut-embedding therapy and auricular point pressure
Number of subjects: 180

Group type: COMPARATOR
Intervention: Auricular point pressure (control group)
Number of subjects: 180
Study: 26151493

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG) 4.5 × 10(9) cfu/d for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG)
Number of subjects: 30
Study: 23322522

Group type: EXPERIMENTAL
Intervention: Combination of epirubicin and paclitaxel alone or with capecitabine (TEX)
Number of subjects: 287

Group type: COMPARATOR
Intervention: New lesions or progression of non-target lesions
Number of subjects: 287
Study: 21163722

Group type: EXPERIMENTAL
Intervention: Fresh diesel exhaust (DE)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fresh secondary organic aerosol (SOA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Clean air (CA)
Number of subjects: 38
Study: 19664904

Group type: EXPERIMENTAL
Intervention: Self-management program for COPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oort approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schmitt procedure
Number of subjects: 0
Study: 17185877

Group type: EXPERIMENTAL
Intervention: Mitiglinide regimen (mitiglinide combined with once daily insulin glargine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intensive insulin regimen (multiple daily insulin regimen of aspart insulin and glargine)
Number of subjects: 9
Study: 14678008

Group type: EXPERIMENTAL
Intervention: 4.5% human albumin solution (HAS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Colloid (Gelofusine)
Number of subjects: 15
Study: 11252546

Group type: EXPERIMENTAL
Intervention: Dermatan sulfate
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 60000
Study: 9562199

Group type: EXPERIMENTAL
Intervention: Adson's test (AT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Costoclavicular maneuver (CCM)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Elevated arm stress test (EAST)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Supraclavicular pressure (SCP)
Number of subjects: 53
Study: 7828256

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 112
Study: 2519937

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg of 0.5% bupivacaine IP
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 1101457

Group type: EXPERIMENTAL
Intervention: Cyclandelate (200 mg four times daily for six weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (for six weeks)
Number of subjects: 24
Study: 30987704

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (oral) for 2 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study: 28624096

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study: 26681704

Group type: EXPERIMENTAL
Intervention: Intervention arm (radio campaign)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 5000
Study: 23426718

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 25
Study: 16817274

Group type: EXPERIMENTAL
Intervention: Point application at Yishu, Pishu, Sanyinjiao, Zusanli, and interference therapy of controlling diet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Interference therapy of controlling diet
Number of subjects: 64
Study: 12696562

Group type: EXPERIMENTAL
Intervention: High-folate diet (at least seven servings of vegetables, berries, and citrus fruit per day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-folate diet (one serving of both vegetables and fruit per day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-folate diet
Number of subjects: 37
Study: 10360858

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.2 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.8 mg/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lidocaine 3 mg/kg
Number of subjects: 15
Study: 7856824

Group type: EXPERIMENTAL
Intervention: P. falciparum antigen detection system (ParaSight F test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard microscopic malaria diagnosis and quantitative buffy coat analysis
Number of subjects: 0
Study: 1928672

Group type: EXPERIMENTAL
Intervention: Thoracic epidural fentanyl combined with 0.2% bupivacaine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Thoracic epidural fentanyl alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study: 7075649

Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg twice daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg retard once daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg retard
Number of subjects: 52
Study: 31370840

Group type: EXPERIMENTAL
Intervention: Best practice case management in the intervention group
Number of subjects: 736

Group type: COMPARATOR
Intervention: Routine care in the control group
Number of subjects: 736
Study: 28427403

Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin (200 ml, 2 h before anesthesia) without ω-3 PUFA (CHO, n=14)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin (200 ml, 2 h before anesthesia) plus intraoperative ω-3 PUFA (0.2 mcg/kg) (CHO + W3, n=15)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Water (200 ml, 2 h before anesthesia) plus intraoperative ω-3 PUFA (0.2 mcg/kg) (W3, n=14)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Water (200 ml, 2 h before anesthesia) without ω-3 PUFA (controls, n=14)
Number of subjects: 57
Study: 25249468

Group type: EXPERIMENTAL
Intervention: Self-management education from disease management nurses for 12 months, followed by 12 months of follow-up.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care for 24 months (control group).
Number of subjects: 31
Study: 23391214

Group type: EXPERIMENTAL
Intervention: Case management by a nurse combined with group support meetings based on the Stanford Chronic Disease Self‐Management Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention control group (six months)
Number of subjects: 0
Study: 21702705

Group type: EXPERIMENTAL
Intervention: Enriched Opportunities Programme (EOP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 200
Study: 18063411

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study: 16829341

Group type: EXPERIMENTAL
Intervention: Dietary change and smoking cessation advice
Number of subjects: 1232
Study: 14669031

Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection of ox-LDL in temporal arteries with biopsy proven temporal arteritis (n=11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls (n=12)
Number of subjects: 23
Study: 10963464

Group type: EXPERIMENTAL
Intervention: Breakfast cereal containing 200 microg of folic acid per serving
Number of subjects: 79

Group type: COMPARATOR
Intervention: Breakfast cereal containing < 10 microg of folic acid per serving (placebo)
Number of subjects: 79
Study: 8923021

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study: 2003044

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study: 6345167

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg daily
Number of subjects: 757
Study: 30861160

Group type: EXPERIMENTAL
Intervention: 4-mg FDA-approved nasal spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-mg FDA-approved autoinjector
Number of subjects: 0

Group type: COMPARATOR
Intervention: Improvised nasal naloxone device (INND) administered twice (2 mg each, separated by 2 minutes)
Number of subjects: 0
Study: 29928996

Group type: EXPERIMENTAL
Intervention: ACT (Acceptance and Commitment Therapy)
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: CEE (Collective Empowerment Education)
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: ACT+CEE (Combination of ACT and CEE)
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2160
Study: 27807084

Group type: COMPARATOR
Intervention: Community-based intervention to improve growth among children under 2 years of age.
Number of subjects: 0
Study: 24909469

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil alone (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cisatracurium (Group B)
Number of subjects: 40
Study: 22381072

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change program (advice on lifestyle and treatment)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 436
Study: 18722112

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) followed by breast conservation surgery with axillary dissection and radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast conservation therapy
Number of subjects: 0
Study: 17204566

Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (1 g/day)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 16360356

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 334
Study: 12062149

Group type: EXPERIMENTAL
Intervention: Objects described as having conceptual properties typical of artifacts; children extended novel labels based on shape alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objects described as having conceptual properties typical of animate kinds; children extended novel labels based on shape and texture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salient perceptual cue (object with eyes labeled in a story context); children extended the label based on shape alone
Number of subjects: 0
Study: 9474617

Group type: EXPERIMENTAL
Intervention: Coumadin (target INR 2.5-3.0) for 22 ± 9 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Winstrol (6 mg per day) for 16 ± 9 weeks
Number of subjects: 26
Study: 7640234

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1546

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 1546
Study: 2191444

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo with antibiotic therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo with adrenal corticosteroid therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (colonized by Candida sp)
Number of subjects: 112
Study: 205020

Group type: EXPERIMENTAL
Intervention: Prophylactic adenine arabinoside (Ara-A) at a dose of 5 mg/kg/day administered intravenously on an intermittent schedule
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prophylactic adenine arabinoside (Ara-A)
Number of subjects: 40
Study: 30634878

Group type: EXPERIMENTAL
Intervention: Face Mirroring System (FMS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional mirror book (MB) therapy
Number of subjects: 36
Study: 30680983

Group type: EXPERIMENTAL
Intervention: sFLT-1/PlGF ratio in preterm delivery group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: sFLT-1/PlGF ratio in preterm delivery PE group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Caesarean delivery in PE group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Complications of preeclampsia in PE group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: sFLT-1/PlGF ratio
Number of subjects: 35
Study: 28111966

Group type: EXPERIMENTAL
Intervention: Exercise training for 12 months
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Patients with albuminuria (n=34)
Number of subjects: 131
Study: 25714582

Group type: EXPERIMENTAL
Intervention: Experimental formula (EF) supplemented with bovine MFGM
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 160
Study: 22791467

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring sensor (CGMS)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Point of care glucose monitors
Number of subjects: 188
Study: 21755716

Group type: EXPERIMENTAL
Intervention: Vicryl* Plus
Number of subjects: 184

Group type: COMPARATOR
Intervention: Vicryl*
Number of subjects: 184
Study: 19785937

Group type: EXPERIMENTAL
Intervention: BMMC therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard medication
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study: 16681333

Group type: EXPERIMENTAL
Intervention: Multi-component tobacco intervention (sports sponsorship, health promotion campaigns, training health professionals, school education about tobacco, policy on smoke-free public places)
Number of subjects: 920

Group type: COMPARATOR
Intervention: Matched control community
Number of subjects: 920
Study: 14652762

Group type: EXPERIMENTAL
Intervention: Children
Number of subjects: 23
Study: 11404379

Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with MAGE peptides (group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dendritic cells pulsed with MAGE peptides plus KLH (group B)
Number of subjects: 26
Study: 9058626

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid for 12 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid + azathioprine + prednisone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 24
Study: 8147083

Group type: EXPERIMENTAL
Intervention: Re-activating occupational therapy (study group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal program of functional rehabilitation (control group)
Number of subjects: 22
Study: 3524169

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20